PHOENIX, March 29, 2018 (GLOBE NEWSWIRE) -- EastGate Biotech Corp. (PinkSheets:ETBI) (the Company) a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug deliver for the treatment of type 2 diabetes, announced CEO, Anna Gluskin and President, Rose Perri interview on Uptick Newswire’s “Stock Day” podcast with Everett Jolly.
“For the last two years we have been working diligently on changing injectable insulin to the alternative delivery format of liquid insulin mouth rinse,” Gluskin commented. “Our goal is to increase compliance by making the insulin easy to administer and affordable.”
EastGate Biotech Corporation has a new office in the Philippines, where the prevalence of diabetes is particularly high. The Company is working with the government and the Ministry of Health to negotiate terms of registering the product.
“We have been working on new avenues of financing,” said Perri who was recently appointed Global Ambassador of United World Against Diabetes, non-for-profit organization. “We are also working on the regulatory pathways, which we have significant experience in North America and other countries. By achieving approval here we will then be able to spread across other countries in Asia and other world markets.”
“The Company has completed an important step in its financing,” Jolly commented. “How will this benefit the company?”
“The financing we had was detrimental to the stock,” Gluskin concluded. “We are now looking for non-dilutive financing, so we can focus on our work.”
To listen to the full interview please click here to the following link: https://upticknewswire.com/featured-interview-ceo-anna-gluskin-of-eastgate-biotech-corp-otcpink-etbi/
About EastGate Biotech
EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increase the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. EastGate's wholly owned subsidiary, Omni Surgery and Anti-Aging Centre, is the first of many surgery centers to come under the Omni umbrella as we plan to roll up existing business under the Omni brand and expand our footprint globally.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
About Uptick Newswire and the “Stock Day” Podcast
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit EastGate Biotech Corp. message board on: https://investorshangout.com/
Source: Uptick Newswire